Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | VCP | P55072 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | PAM | P19021 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28586536 | 0.97 | NPSR1 (0.57) | NPSR1APPVCPNPC1RAB9A | |
| SCHEMBL17957122 | 0.97 | NPSR1 (0.57) | NPSR1APPVCPNPC1RAB9A | |
| SCHEMBL18530660 | 0.97 | NPSR1 (0.57) | NPSR1APPVCPNPC1RAB9A | |
| SCHEMBL11081761 | 0.89 | NPSR1 (0.55) | NPSR1APPVCPNPC1RAB9A | |
| SCHEMBL68968 | 0.84 | NPSR1 (0.59) | NPSR1APPVCPNPC1RAB9A | |
| SCHEMBL8103677 | 0.84 | NPSR1 (0.59) | NPSR1APPVCPNPC1RAB9A | |
| Benzene SCHEMBL28174766 | 0.84 | NPSR1 (0.59) | NPSR1APPVCPNPC1RAB9A | |
| SCHEMBL6241543 | 0.84 | MAOA (0.50) | NPSR1APPVCPNPC1RAB9A | |
| SCHEMBL7590817 | 0.84 | NPSR1 (0.50) | NPSR1APPVCPNPC1RAB9A | |
| SCHEMBL6243540 | 0.84 | FFAR1 (0.60) | NPSR1NPC1RAB9AFFAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107949596-B | Semi-crystalline polyamide component with high glass transition temperature for composite materials, method for the production thereof and use thereof | 阿科玛法国公司 | 2021-02-02 | — | — | CN | claimed |
| CN-115197565-B | Semi-crystalline polyamide composition based on short diamines with high glass transition temperature, process for its production and use thereof | 阿科玛法国公司 | 2024-10-11 | — | — | CN | disclosed |
| EP-2943826-B1 | LAYERS OR THREE-DIMENSIONAL SHAPED BODIES HAVING TWO REGIONS OF DIFFERENT PRIMARY AND/OR SECONDARY STRUCTURE, METHOD FOR PRODUCTION THEREOF AND MATERIALS FOR CONDUCTING THIS METHOD | FRAUNHOFER GES FORSCHUNG (DE) | 2023-08-02 | — | — | EP | disclosed |
| CN-115197565-A | Semi-crystalline polyamide composition based on short diamines with high glass transition temperature, method for the production thereof and use thereof | 阿科玛法国公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-110446740-B | Semi-crystalline polyamide compositions based on short diamines with high glass transition temperature, method for the production thereof and use thereof | 阿科玛法国公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-110431169-B | Semi-crystalline polyamide composition having a high glass transition temperature and a high melting temperature, method for preparing same and use thereof | 阿科玛法国公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-107949596-B | Semi-crystalline polyamide component with high glass transition temperature for composite materials, method for the production thereof and use thereof | 阿科玛法国公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-108026267-B | Semi-crystalline polyamide composition with high glass transition temperature for thermoplastic materials, method for the production thereof and use thereof | 阿科玛法国公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-2943825-B1 | LAYERS OR THREE-DIMENSIONAL SHAPED BODIES HAVING TWO REGIONS OF DIFFERENT PRIMARY AND/OR SECONDARY STRUCTURE AND METHOD FOR PRODUCTION THEREOF | FRAUNHOFER GES FORSCHUNG (DE) | 2018-12-12 | — | — | EP | disclosed |
| US-20180111889-A1 | METHODS OF MAKING MULTICYCLIC COMPOUNDS USING MULTICOMPONENT/TANDEM REACTION SEQUENCES | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2018-04-26 | — | — | US | disclosed |
| CN-101068810-A | Carbostyril compound | OTSUKA PHARMA CO LTD (JP) | 2007-11-07 | — | — | CN | disclosed |
| CN-1902169-A | 4-biaryl-1-phenylazetidin-2-ones | MICROBIA INC (US) | 2007-01-24 | — | — | CN | disclosed |
| CN-1826345-A | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORP A CORP OF THE ST (US) | 2006-08-30 | — | — | CN | disclosed |
| CN-1688545-A | phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | disclosed |
| CN-1432019-A | Hygromycin derivatives for treatment of bacterial and protozoal infections | PFIZER PROD INC (US) | 2003-07-23 | — | — | CN | disclosed |
| US-4689321-A | CYTOLYSIS, ANTITUMOR, ANTICARCINOGENIC | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1987-08-25 | — | — | US | disclosed |
| US-4431586-A | Monocyclic telluropyrones | EASTMAN KODAK COMPANY (US) | 1984-02-14 | — | — | US | disclosed |
| US-4179561-A | REACTING A 3-DIAZOOXINDOLE WITH A SUBSTITUTED ACETYLENE | E. R. SQUIBB & SONS, INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4112096-A | ANTIALLERGENS | E. R. SQUIBB & SONS, INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4076818-A | ANTIALLERGENS | E. R. SQUIBB & SONS, INC. (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111889-A1 | METHODS OF MAKING MULTICYCLIC COMPOUNDS USING MULTICOMPONENT/TANDEM REACTION SEQUENCES | TYMS, RTCB, POLRMT | NPSR1 2585/4885APP 2739/4885VCP 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.